Araceli Brugge-Oostende Diez-Fraile

Dr. Araceli Brugge-Oostende Diez-Fraile

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
JCJoke De Ceulaer
Joke De Ceulaer
CDCharlotte Derpoorter
Charlotte Derpoorter
CSChristophe Spaas
Christophe Spaas
TBTom De Backer
Tom De Backer
TLTim Lammens
Tim Lammens
Head and neck cancer (HNC), the seventh most common form of cancer worldwide, is a group of epithelial malignancies affecting sites in the upper aerodigestive tract. The 5-year overall survival for patients with HNC has stayed around 40–50% for decades, with mortality being attributable mainly to late diagnosis and recurrence. Recently, non-coding RNAs, including tRNA halves, YRNA fragments, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), have been identified in the blood and saliva of patients diagnosed with HNC. These observations have recently fueled the study of their potential use in early detection, diagnosis, and risk assessment. The present review focuses on recent insights and the potential impact that circulating non-coding RNA evaluation may have on clinical decision-making in the management of HNC.

Verified
Journal Article
Open access
PDF file
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
JCJoke De Ceulaer
Joke De Ceulaer
CDCharlotte Derpoorter
Charlotte Derpoorter
CSChristophe Spaas
Christophe Spaas
TBTom De Backer
Tom De Backer
TLTim Lammens
Tim Lammens
The 5-year relative survival for patients with head and neck cancer, the seventh most common form of cancer worldwide, was reported as 67% in developed countries in the second decade of the new millennium. Although surgery, radiotherapy, chemotherapy, or combined treatment often elicits an initial satisfactory response, relapses are frequently observed within two years. Current surveillance methods, including clinical exams and imaging evaluations, have not unambiguously demonstrated a survival benefit, most probably due to a lack of sensitivity in detecting very early recurrence. Recently, liquid biopsy monitoring of the molecular fingerprint of head and neck squamous cell carcinoma has been proposed and investigated as a strategy for longitudinal patient care. These innovative methods offer rapid, safe, and highly informative genetic analysis that can identify small tumors not yet visible by advanced imaging techniques, thus potentially shortening the time to treatment and improving survival outcomes. In this review, we provide insights into the available evidence that the molecular tumor fingerprint can be used in the surveillance of head and neck squamous cell carcinoma. Challenges to overcome, prior to clinical implementation, are also discussed.


2 July 2025 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
YWYves Weinberg
Yves Weinberg
Giovanni AudinoGiovanni Audino
Giovanni Audino
AAA. Aksu
A. Aksu
FRF. Reinauer
F. Reinauer
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
GSG.R.J. Swennen
G.R.J. Swennen

9 March 2012
Verified
Book Chapter
Open access
PDF file
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
NVNico Van
Nico Van
CJChristopher J.
Christopher J.
KDKatharina Dherde
Katharina Dherde
Optimizing Multiple Immunostaining of Neural Tissue | InTechOpen, Published on: 2012-03-09. Authors: Araceli Diez-Fraile, Nico Van Hecke, Christopher J. Guérin, et

7 August 2026 in American Journal of Orthodontics and Dentofacial Orthopedics
Verified
Journal Article
Open access
LBLieselotte De Bruyn
Lieselotte De Bruyn
Veronica ScoccaVeronica Scocca
Veronica Scocca
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
GSGwen R.J. Swennen
Gwen R.J. Swennen